Assessment of neurotoxicity from potential medications for drug abuse: ibogaine testing and brain imaging.
Annals of the New York Academy of Sciences May 30, 1997 F J Vocci, E D London 6 citations
New brain-monitoring technologies can detect pharmacological effects more sensitively than clinical exams, but each detected change must be assessed for clinical significance. Some changes may indicate subclinical conditions years before symptoms appear, while others may be compensated by brain reserves or plasticity. Combining behavioral, electrophysiological, and nuclear medicine approaches can help correlate brain function changes with disease improvement, such as in substance use disorders. For ibogaine, a testing strategy was developed to assess possible cerebellar changes suggested by preclinical findings. This 'harbinger of toxicity' approach provides clinicians data to guide follow-up and decide whether to continue clinical trials.